Twist Bioscience (NASDAQ:TWST – Get Free Report) had its price objective decreased by investment analysts at Barclays from $215.00 to $130.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 24.33% from the stock’s current price.
A number of other research analysts also recently issued reports on TWST. Jefferies Financial Group set a $125.00 price target on shares of Twist Bioscience in a research note on Thursday. Leerink Partners dropped their price objective on shares of Twist Bioscience from $190.00 to $175.00 and set an “outperform” rating on the stock in a research report on Friday. Guggenheim raised their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 1st. TD Cowen decreased their price objective on shares of Twist Bioscience from $190.00 to $137.00 and set a “buy” rating for the company in a research report on Friday. Finally, Canaccord Genuity Group decreased their price objective on shares of Twist Bioscience from $205.00 to $150.00 and set a “buy” rating for the company in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $133.92.
View Our Latest Research Report on TWST
Twist Bioscience Stock Down 6.3%
NASDAQ TWST traded down $7.04 during trading hours on Monday, hitting $104.56. 593,086 shares of the company were exchanged, compared to its average volume of 1,783,855. The company has a 50 day moving average of $150.23 and a two-hundred day moving average of $93.07. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 52-week low of $24.41 and a 52-week high of $219.71. The firm has a market cap of $6.56 billion, a price-to-earnings ratio of -49.88 and a beta of 2.25.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The business had revenue of $126.64 million during the quarter, compared to analysts’ expectations of $123.55 million. The company’s revenue was up 26.7% compared to the same quarter last year. Equities research analysts anticipate that Twist Bioscience will post -1.52 earnings per share for the current year.
Insider Activity
In other Twist Bioscience news, CAO Robert F. Werner sold 1,482 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $279,920.16. Following the sale, the chief accounting officer owned 42,917 shares of the company’s stock, valued at approximately $8,106,162.96. This trade represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 1,007 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total transaction of $136,347.80. Following the sale, the senior vice president directly owned 105,625 shares in the company, valued at approximately $14,301,625. The trade was a 0.94% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 495,279 shares of company stock valued at $80,489,387 over the last 90 days. Insiders own 3.08% of the company’s stock.
Institutional Investors Weigh In On Twist Bioscience
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Entropy Technologies LP boosted its stake in Twist Bioscience by 69.8% in the third quarter. Entropy Technologies LP now owns 19,357 shares of the company’s stock valued at $3,741,000 after acquiring an additional 7,955 shares in the last quarter. Pathstone Holdings LLC purchased a new position in shares of Twist Bioscience during the third quarter worth about $474,000. Empowered Funds LLC increased its position in shares of Twist Bioscience by 182.6% during the third quarter. Empowered Funds LLC now owns 5,881 shares of the company’s stock worth $1,136,000 after purchasing an additional 3,800 shares in the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of Twist Bioscience by 99.0% during the third quarter. Steward Partners Investment Advisory LLC now owns 203 shares of the company’s stock worth $39,000 after purchasing an additional 101 shares in the last quarter. Finally, New World Advisors LLC purchased a new stake in shares of Twist Bioscience in the 3rd quarter valued at about $267,000.
About Twist Bioscience
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
See Also
- Five stocks we like better than Twist Bioscience
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
